Helix BioPharma Corp. Completes Enrollment In Its Phase II Trial Of Topical Interferon Alpha-2b In Patients With Ano-Genital Warts
Links shared publicly online about this topic.
- 1,622total visits
Helix BioPharma Corp. Completes Enrollment In Its Phase II Trial Of Topical Interferon Alpha-2b In Patients With Ano-Genital Warts
Helix BioPharma Corp. (TSX, FSE: HBP / OTCQX: HXBPF) announced that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollmen
View full resource at medicalnewstoday.com
Tags: Heart Disease, High Blood Pressure, Wart
Most Recently Shared on November 6, 2009 at 3:21 pm By:
Helix BioPharma Corp. Completes Enrollment In Its Phase II Trial Of Topical Interferon Alpha-2b In Patients Wit.. http://bit.ly/IbiLS
Advertisement
